About Endogenous retrovirus group K member 8 Pol protein
Endogenous retrovirus group K member 8 Pol protein (ERVK-8) is a protein
from Homo sapiens identified by UniProt accession
P63133, 956 residues long.
MolForge cross-references it against 0 known binders and
0 disease associations.
Target properties
| Protein name | Endogenous retrovirus group K member 8 Pol protein |
|---|
| UniProt accession | P63133 |
|---|
| Gene | ERVK-8 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 956 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P63133-F1 | alphafold | PREDICTED | 80.38 | — |
Amino-acid sequence (956 residues)
NKSKKRRNRV SFLGVATIEP PKPIPLTWKT EKLVWVNQWP LPKQKLEALH LLANEQLEKG HIEPSFSPWN SPVFVIQKKS GKWRMLTDLR AVNAVIQPMG PLQPGLPSPA MIPKDWPLII IDLKDCFFTI PLAEQDCEKF AFTIPAINNK EPATRFQWKV LPQGMLNSPT ICQTFVGRAL QPVRKKFSDC YIIHYIDDIL CAAETKDKLI DCYTFLQAEV ASAGLAIASD KIQTSTPFHY LGMQIENRKI KPQKIEIRKD TLKTLNDFQK LLGDINWIQP TLGIPTYAMS NLFSILRGDS DLNSKRILTP EATKEIKLVE EKIQSAQINR IDPLAPLQLL IFATAHSPTG IIIQNTDLVE WSFLPHSTVK TFTLYLDQIA TLIGQTRLRI IKLCGNDPDK IVVPLTKEQV RQAFINSGAW QIGLANFVGI IDNHYPKTKI FQFLKLTTWI LPKITRREPL ENALTVFTDG SSNGKAAYTG PKERVIKTPY QSAQRAELVA VITVLQDFDQ PINIISDSAY VVQATRVVET ALIKYSMDDQ LNQLFNLLQQ TVRKRNFPFY ITHIRAHTNL PGPLTKANEQ ADLLVSSALI KAQELHALTH VNAAGLKNKF DVTWKQAKDI VQHCTQCQVL HLPTQEAGVN PRGLCPNALW QMDVTHVPSF GRLSYVHVTV DTYSHFIWAT CQTGESTSHV KKHLLSCFAV MGVPEKIKTD NGPGYCSKAF QKFLSQWKIS HTTGIPYNSQ GQAIVERTNR TLKTQLVKQK EGGDSKECTT PQMQLNLALY TLNFLNIYRN QTTTSAEQHL TGKKNSPHEG KLIWWKDNKN KTWEIGKVIT WGRGFACVSP GENQLPVWIP TRHLKFYNEP IRDAKKSTSA ETETPQSSTV DSQDEQNGDV RRTDEVAIHQ EGRAADLGTT KEADAVSYKI SREHKGDTNP REYAACSLDD CINGGKSPYA CRSSCS
Explore Endogenous retrovirus group K member 8 Pol protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets